Mayo Clinic receives $200M gift

A philanthropist has given $200 million to Mayo Clinic in what is the largest-ever donation to the nonprofit hospital system.

Jay Alix, of Birmingham, Michigan, is founder of the turnaround consultancy firm AlixPartners and the philanthropist behind the endowment gift. The money is designated to Mayo Clinic School of Medicine, which will be renamed Mayo Clinic Alix School of Medicine.

The gift will expand scholarship opportunities, spur innovation in the school’s curriculum and establish a professorship, according to a press release.

Alix is a Mayo Clinic patient, member of the board of trustees and co-chair of Mayo’s global advisory council.

“Genetics, artificial intelligence, virtual and augmented reality and other technologies are transforming medical research, education and practice,” Alix said in a statement. “This gift will further enable Mayo’s medical school to recruit the best medical students and to create a curriculum that trains them to harness evolving radical advances in medical science and technology to the greatest benefit of patients.” 

The gift was announced on the heels of another major donation in the medical school space, after The Blavatnik Family Foundation pledged $200 million to Harvard Medical School.

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.